However, administration of FSTL1 reduced ischemic damage and inflammatory response with AMP-activated protein kinase- and bone morphogenetic protein-4-dependent mechanisms in a myocardial infarction model [58]. The gene discussed is BMP4; the disease is myocardial infarction.